179 related articles for article (PubMed ID: 37852607)
1. Case study: breakthrough mpox infection in Aotearoa New Zealand and Australia after completed two-dose course of subcutaneous modified vaccinia Ankara (MVA-BN) vaccines.
Cornelisse VJ; Kearley JJM; Vargas Castillo J; Macharg L; McLaughlin VA; Jack SJ; Swift C
Sex Health; 2023 Dec; 20(6):585-587. PubMed ID: 37852607
[TBL] [Abstract][Full Text] [Related]
2. Early evaluation of the safety, reactogenicity, and immune response after a single dose of modified vaccinia Ankara-Bavaria Nordic vaccine against mpox in children: a national outbreak response.
Ladhani SN; Dowell AC; Jones S; Hicks B; Rowe C; Begum J; Wailblinger D; Wright J; Owens S; Pickering A; Shilltoe B; McMaster P; Whittaker E; Zuo J; Powell A; Amirthalingam G; Mandal S; Lopez-Bernal J; Ramsay ME; Kissane N; Bell M; Watson H; Ho D; Hallis B; Otter A; Moss P; Cohen J
Lancet Infect Dis; 2023 Sep; 23(9):1042-1050. PubMed ID: 37336224
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of Modified Vaccinia Ankara-Bavaria Nordic Vaccination in a Population at High Risk of Mpox: A Spanish Cohort Study.
Fontán-Vela M; Hernando V; Olmedo C; Coma E; Martínez M; Moreno-Perez D; Lorusso N; Vázquez Torres M; Barbas Del Buey JF; Roig-Sena J; Pastor E; Galmés Truyols A; Artigues Serra F; Sancho Martínez RM; Latasa Zamalloa P; Pérez Martínez O; Vázquez Estepa A; García Rojas AJ; Barreno Estévez AI; Sánchez-Migallón Naranjo A; Pérez Martín JJ; Peces Jiménez P; Morales Romero R; Castilla J; García Cenoz M; Huerta Huerta M; Boone ALD; Macías Ortiz MJ; Álvarez Río V; Rodríguez Recio MJ; Merino Díaz M; Berradre Sáenz B; Villegas-Moreno MT; Limia A; Diaz A; Monge S;
Clin Infect Dis; 2024 Feb; 78(2):476-483. PubMed ID: 37864849
[TBL] [Abstract][Full Text] [Related]
4. Outcomes of post-exposure vaccination by modified vaccinia Ankara to prevent mpox (formerly monkeypox): a retrospective observational study in Lyon, France, June to August 2022.
Merad Y; Gaymard A; Cotte L; Perpoint T; Alfaiate D; Godinot M; Becker A; Cannesson O; Batalla AS; Oria-Yassir F; Landré S; Morfin F; Bouscambert M; Valour F; Ader F; Conrad A
Euro Surveill; 2022 Dec; 27(50):. PubMed ID: 36695469
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of one dose of MVA-BN smallpox vaccine against mpox in England using the case-coverage method: an observational study.
Bertran M; Andrews N; Davison C; Dugbazah B; Boateng J; Lunt R; Hardstaff J; Green M; Blomquist P; Turner C; Mohammed H; Cordery R; Mandal S; Campbell C; Ladhani SN; Ramsay M; Amirthalingam G; Bernal JL
Lancet Infect Dis; 2023 Jul; 23(7):828-835. PubMed ID: 36924787
[TBL] [Abstract][Full Text] [Related]
6. Real-world effectiveness of a single dose of mpox vaccine in males.
Wolff Sagy Y; Zucker R; Hammerman A; Markovits H; Arieh NG; Abu Ahmad W; Battat E; Ramot N; Carmeli G; Mark-Amir A; Wagner-Kolasko G; Duskin-Bitan H; Yaron S; Peretz A; Arbel R; Lavie G; Netzer D
Nat Med; 2023 Mar; 29(3):748-752. PubMed ID: 36720271
[TBL] [Abstract][Full Text] [Related]
7. Characterizing the acute antibody response of monkeypox and MVA-BN vaccine following an Australian outbreak.
Asquith W; Hueston L; Dwyer D; Kok J; Ko D; Fennel M; Rockett R; Rai NJ; Li Y; Sriramoju S; Sutor A; O'Sullivan M
J Med Virol; 2024 Jan; 96(1):e29407. PubMed ID: 38240403
[TBL] [Abstract][Full Text] [Related]
8. Asymptomatic and Subclinical Mpox: An Association With Modified Vaccinia Ankara Vaccine.
Golden MR; Soge OO; Mills M; Berzkalns A; Cannon C; Ramchandani M; Dombrowski JC; Karmarkar EN; Chow EJ; Gov JP; Swenson P; Greninger AL
Sex Transm Dis; 2024 May; 51(5):342-347. PubMed ID: 38301634
[TBL] [Abstract][Full Text] [Related]
9. Clinical characteristics of mpox infection in individuals who received a first dose of modified vaccinia Ankara immunisation.
Agunbiade S; Burton F; Muirhead J; Whitlock GG; Girometti N
Sex Transm Infect; 2023 May; 99(3):198-199. PubMed ID: 36596674
[TBL] [Abstract][Full Text] [Related]
10. Prospective monitoring of adverse events following vaccination with Modified vaccinia Ankara - Bavarian Nordic (MVA-BN) administered to a Canadian population at risk of Mpox: A Canadian Immunization Research Network study.
Muller MP; Navarro C; Wilson SE; Shulha HP; Naus M; Lim G; Padhi S; McGeer A; Finkelstein M; Liddy A; Bettinger JA;
Vaccine; 2024 Jan; 42(3):535-540. PubMed ID: 38199921
[TBL] [Abstract][Full Text] [Related]
11. Mpox in people with past infection or a complete vaccination course: a global case series.
Hazra A; Zucker J; Bell E; Flores J; Gordon L; Mitjà O; Suñer C; Lemaignen A; Jamard S; Nozza S; Nori AV; Pérez-Barragán E; Rodríguez-Aldama JC; Blanco JL; Delaugerre C; Turner D; Fuertes I; Leiro V; Walmsley SL; Orkin CM;
Lancet Infect Dis; 2024 Jan; 24(1):57-64. PubMed ID: 37678309
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the immunogenicity and protective efficacy of ACAM2000, MVA, and vectored subunit vaccines for Mpox in rhesus macaques.
Jacob-Dolan C; Ty D; Hope D; McMahan K; Liu J; Powers OC; Cotter CA; Sciacca M; Wu C; Borducchi E; Bouffard E; Richter H; Velasco J; Teow E; Boursiquot M; Cook A; Feliciano K; Yalley-Ogunro J; Seaman MS; Pessiant L; Lewis MG; Andersen H; Moss B; Barouch DH
Sci Transl Med; 2024 Mar; 16(740):eadl4317. PubMed ID: 38536937
[TBL] [Abstract][Full Text] [Related]
13. Short-term Adverse Events Following Immunization With Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) Vaccine for Mpox.
Deng L; Lopez LK; Glover C; Cashman P; Reynolds R; Macartney K; Wood N
JAMA; 2023 Jun; 329(23):2091-2094. PubMed ID: 37145654
[TBL] [Abstract][Full Text] [Related]
14. Complement-dependent mpox-virus-neutralizing antibodies in infected and vaccinated individuals.
Hubert M; Guivel-Benhassine F; Bruel T; Porrot F; Planas D; Vanhomwegen J; Wiedemann A; Burrel S; Marot S; Palich R; Monsel G; Diombera H; Gallien S; Lopez-Zaragoza JL; Vindrios W; Taieb F; Fernandes-Pellerin S; Delhaye M; Laude H; Arowas L; Ungeheuer MN; Hocqueloux L; Pourcher V; Prazuck T; Marcelin AG; Lelièvre JD; Batéjat C; Lévy Y; Manuguerra JC; Schwartz O
Cell Host Microbe; 2023 Jun; 31(6):937-948.e4. PubMed ID: 37196656
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of JYNNEOS Vaccine Against Diagnosed Mpox Infection - New York, 2022.
Rosenberg ES; Dorabawila V; Hart-Malloy R; Anderson BJ; Miranda W; O'Donnell T; Gonzalez CJ; Abrego M; DelBarba C; Tice CJ; McGarry C; Mitchell EC; Boulais M; Backenson B; Kharfen M; McDonald J; Bauer UE
MMWR Morb Mortal Wkly Rep; 2023 May; 72(20):559-563. PubMed ID: 37339074
[TBL] [Abstract][Full Text] [Related]
16. Breakthrough cases of mpox: One-dose vaccination is associated with milder clinical manifestations.
Allard R; Leclerc P; Bergeron G; Cadieux G
J Infect Public Health; 2024 Apr; 17(4):676-680. PubMed ID: 38461797
[TBL] [Abstract][Full Text] [Related]
17. Predicting vaccine effectiveness for mpox.
Berry MT; Khan SR; Schlub TE; Notaras A; Kunasekaran M; Grulich AE; MacIntyre CR; Davenport MP; Khoury DS
Nat Commun; 2024 May; 15(1):3856. PubMed ID: 38719852
[TBL] [Abstract][Full Text] [Related]
18. Safety and Efficacy of Post-Eradication Smallpox Vaccine as an Mpox Vaccine: A Systematic Review with Meta-Analysis.
Malone SM; Mitra AK; Onumah NA; Brown A; Jones LM; Tresvant D; Brown CS; Onyia AU; Iseguede FO
Int J Environ Res Public Health; 2023 Feb; 20(4):. PubMed ID: 36833653
[TBL] [Abstract][Full Text] [Related]
19. Progress and prospects on vaccine development against monkeypox infection.
Saadh MJ; Ghadimkhani T; Soltani N; Abbassioun A; Daniel Cosme Pecho R; Taha A; Jwad Kazem T; Yasamineh S; Gholizadeh O
Microb Pathog; 2023 Jul; 180():106156. PubMed ID: 37201635
[TBL] [Abstract][Full Text] [Related]
20. Mpox vaccination and treatment: a systematic review.
Eslami A; Alimoghadam S; Khoshravesh S; Shirani M; Alimoghadam R; Alavi Darazam I
J Chemother; 2024 Apr; 36(2):85-109. PubMed ID: 38069596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
